News coverage about AZN stock has been trending somewhat negative this week, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. AstraZeneca earned a news impact score of -1.6 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days.

View the latest news about AstraZeneca.